Brokerages forecast that Urogen Pharma Ltd (NASDAQ:URGN) will report earnings per share (EPS) of ($1.22) for the current quarter, Zacks reports. Zero analysts have issued estimates for Urogen Pharma’s earnings, with the lowest EPS estimate coming in at ($1.33) and the highest estimate coming in at ($1.11). Urogen Pharma posted earnings per share of ($1.14) in the same quarter last year, which indicates a negative year over year growth rate of 7%. The company is expected to issue its next quarterly earnings results on Tuesday, August 13th.
According to Zacks, analysts expect that Urogen Pharma will report full year earnings of ($5.41) per share for the current financial year, with EPS estimates ranging from ($5.83) to ($5.06). For the next fiscal year, analysts forecast that the company will post earnings of ($3.89) per share, with EPS estimates ranging from ($6.27) to ($1.66). Zacks’ earnings per share calculations are a mean average based on a survey of sell-side research analysts that cover Urogen Pharma.
Urogen Pharma (NASDAQ:URGN) last announced its earnings results on Thursday, May 9th. The company reported ($1.11) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.12) by $0.01. Urogen Pharma had a negative net margin of 4,296.08% and a negative return on equity of 61.24%.
In related news, insider Mark Schoenberg sold 1,991 shares of Urogen Pharma stock in a transaction on Wednesday, March 6th. The shares were sold at an average price of $37.30, for a total value of $74,264.30. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 10.50% of the company’s stock.
A number of large investors have recently bought and sold shares of the stock. FMR LLC grew its position in Urogen Pharma by 5.8% in the 1st quarter. FMR LLC now owns 588,203 shares of the company’s stock valued at $21,728,000 after buying an additional 32,200 shares during the last quarter. Wildcat Capital Management LLC grew its position in Urogen Pharma by 27.2% in the 1st quarter. Wildcat Capital Management LLC now owns 779,003 shares of the company’s stock valued at $28,776,000 after buying an additional 166,509 shares during the last quarter. Morgan Stanley grew its position in Urogen Pharma by 65.4% in the 1st quarter. Morgan Stanley now owns 24,923 shares of the company’s stock valued at $920,000 after buying an additional 9,856 shares during the last quarter. Man Group plc grew its position in Urogen Pharma by 49.5% in the 1st quarter. Man Group plc now owns 178,996 shares of the company’s stock valued at $6,612,000 after buying an additional 59,260 shares during the last quarter. Finally, Goldman Sachs Group Inc. grew its position in Urogen Pharma by 267.4% in the 1st quarter. Goldman Sachs Group Inc. now owns 59,445 shares of the company’s stock valued at $2,196,000 after buying an additional 43,266 shares during the last quarter. Hedge funds and other institutional investors own 81.77% of the company’s stock.
Shares of URGN opened at $37.74 on Friday. The company has a market cap of $518.93 million, a PE ratio of -7.86 and a beta of 1.33. Urogen Pharma has a 12-month low of $34.61 and a 12-month high of $62.78.
About Urogen Pharma
UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing novel therapies for urological pathologies. The company's lead product candidates, UGN-101 and UGN-102 are proprietary formulations of the chemotherapy drug mitomycin, a generic drug, which is currently used off-label for urothelial cancer treatment in a water-based formulation as an adjuvant or supplemental in post-surgery therapy.
Recommended Story: Trading Strategy Methods for Individual Investors
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Urogen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urogen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.